London, 27th November 2023  

Celix Pharma reports profitability in its first year of commercial operations

Celix Pharma, a start-up generic pharmaceutical company based in London, is pleased to announce its achievement of profitability in its inaugural year of commercial operation: FY22-23. This milestone underscores the company's unwavering dedication to innovation, quality and agility, as evidenced by its filing of 17 products, securing 12 approvals and 6 product launches by the end of FY22-23. 

Celix Pharma currently has 9 products on the market. Looking forward, the company has ambitious plans for several new product launches in FY23-24 (and beyond) and is actively seeking talented and passionate individuals to join its team and contribute to its exciting journey.

Expressing his delight, Subir Kohli, CEO of Celix Pharma, stated, "We are thrilled to have achieved profitability in our first year of commercial operation. This significant milestone underscores our commitment to developing and launching high-quality generic drugs that cater to the needs of our customers and ultimately, the patients."

Shantreddy, COO of Celix Pharma, added, "Celix Pharma's rapid launch of six products within a short timeframe is a testament to our execution orientation and adaptability. We eagerly anticipate the company's future prospects and remain committed to fostering innovation and maintaining superior quality."

VS Vasudevan, an early investor and board member of Celix Pharma, commented, "Celix Pharma's achievement of profitability in its first year of commercial operation reflects its robust business model and operational efficiency. We are excited about Celix Pharma's future prospects and look forward to supporting its continued growth and success."